Clinical trials: Recurrent Glioblastoma Multiforme(GBM)
Advanced Solid Tumors, Solid Tumor
A Trial of Belzutifan (PT2977, MK-6482) Tablets In Patients With Advanced Solid Tumors (MK-6482-001)
The primary objective of this study is to identify the maximum tolerated dose (MTD) of belzutifan Tablets and/or the recommended Phase 2 dose (RP2D) of belzutifan Tablets in patients with advanced solid tumors
- Conditions
- Advanced Solid Tumors, Solid Tumor, Solid Carcinoma, Solid Tumor, Adult
- Trial name
- NCT02974738
- Testing
- Belzutifan
- Volunteers
- 120 people
- Sponsor
- Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Glioblastoma, Gliosarcoma
Ultrasound-based Blood-brain Barrier Opening and Albumin-bound Paclitaxel and Carboplatin for Recurrent Glioblastoma
Paclitaxel is among the most active agents against glioblastoma in preclinical models. However, its clinical use has been hampered by the blood-brain barrier (BBB).
- Conditions
- Glioblastoma, Gliosarcoma, GBM, Glioblastoma Multiforme
- Trial name
- SC9/ABX (NCT04528680)
- Testing
- Sonication for opening of blood-brain barrier, Chemotherapy, albumin-bound paclitaxel, Chemotherapy, carboplatin
- Where
- United States
- Volunteers
- 57 people
- Sponsor
- Northwestern University
Recurrent Glioblastoma, Glioblastoma IDH (Isocitrate Dehydrogenase) Wildtype
Novel Indenoisoquinolone CMYC/TOPOISOMERASE 1 Inhibitor (LMP744) in Recurrent Glioblastoma
Background: Glioblastoma is a common brain cancer in adults. Treatment includes surgery, radiation, and chemotherapy. But this cancer can return after treatment and is often fatal.
- Conditions
- Recurrent Glioblastoma, Glioblastoma IDH (Isocitrate Dehydrogenase) Wildtype, Relapsed Cancer, Recurrent Tumor
- Trial name
- NCT07416188
- Testing
- LMP744, Conventional Surgery or Biopsy
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- National Institute of Neurological Disorders and Stroke (NINDS)
Recurrent Glioblastoma Multiforme(GBM)
A Phase Ib/II Clinical Trial to Evaluate the Safety and Efficacy of JL15003 Injection in Patients With Recurrent Glioblastoma (rGBM)
The goal of this clinical trial is to evaluate the safety and efficacy of JL15003 Injection in subjects with recurrent glioblastoma (rGMB).
- Trial name
- NCT07501559
- Testing
- JL15003Injection
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Jecho Biopharmaceuticals Co., Ltd.
Recurrent Glioblastoma Multiforme(GBM)
A Study to Evaluate Safety and Efficacy of ACT001 and Anti-PD-1 in Patients With Surgically Accessible Recurrent Glioblastoma Multiforme
The current design provides a window to analyze the impact of the ACT001+Pembrolizumab combination on the tumor microenvironment and disease outcomes.
- Trial name
- NCT05053880
- Testing
- ACT001, ACT001 + Pembrolizumab
- Where
- United States
- Volunteers
- 48 people
- Sponsor
- Accendatech USA Inc.
Recurrent Glioblastoma, Glioblastoma Multiforme
Sonodynamic Therapy in Patients With Recurrent GBM
Patients diagnosed with glioblastoma (GBM) are faced with limited treatment options. This pilot study will evaluate the safety and feasibility of combining an investigational drug called 5-ALA with neuronavigation-guided…
- Conditions
- Recurrent Glioblastoma, Glioblastoma Multiforme, GBM
- Trial name
- GBM 001 (NCT06039709)
- Testing
- 5-ALA and Low-Intensity Focused Ultrasound (SDT)
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- Shayan Moosa, MD
Recurrent Glioblastoma Multiforme(GBM)
A Phase I Study to Evaluate the Safety and Tolerability of JL15003 Injection in Patients With Recurrent Glioblastoma
This is a single-arm, open-label, single-dose study consisting of a dose-escalation phase followed by a dose-expansion phase. Four dose levels are planned.
- Trial name
- JL15003 (NCT07497373)
- Testing
- JL15003 Injection
- Where
- 3 sites in China
- Volunteers
- 17 people
- Sponsor
- Jecho Biopharmaceuticals Co., Ltd.
Glioblastoma, Melanoma Stage IV
A Phase 1-2 Study of ST101 in Patients With Advanced Solid Tumors
This is an open-label, two-part, phase 1-2 dose-finding study designed to determine the safety, tolerability, PK, PD, and proof-of-concept efficacy of ST101 administered IV in patients with advanced solid tumors.
- Conditions
- Glioblastoma, Melanoma Stage IV, Breast Cancer, Prostate Cancer
- Trial name
- NCT04478279
- Testing
- ST101, Temozolomide, Radiation
- Where
- 11 sites in United States, United Kingdom
- Volunteers
- 125 people
- Sponsor
- Sapience Therapeutics
Recurrent Glioblastoma Multiforme (GBM)
The Safety and Efficacy of SNC-109 CAR-T Cells Therapy the rGBM
A phase I study to evaluate the safety, tolerance and pharmacokinetics of SNC109 in patients with rGBM
- Trial name
- NCT06616727
- Testing
- SNC109
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Shanghai Simnova Biotechnology Co.,Ltd.
Recurrent Glioblastoma Multiforme (GBM), Grade 3 Isocitrate Dehydrogenase (IDH) Wildtype Astrocytoma
Study of Icapamespib (PU-AD) in Patients With Recurrent Malignant Glioma
This is a 2-part multicenter Phase 1b study designed to test icapamespib in patients with recurrent brain lesions. Part 1 of the trial will be a standard 3 by 3 dose escalation design where different doses are examined.
- Conditions
- Recurrent Glioblastoma Multiforme (GBM), Grade 3 Isocitrate Dehydrogenase (IDH) Wildtype Astrocytoma, Grade 3 or 4 Astrocytoma, Glioblastoma Surgery
- Trial name
- Glio (NCT04782609)
- Testing
- Icapamespib
- Where
- 5 sites in United States
- Volunteers
- 7 people
- Sponsor
- Samus Therapeutics, Inc.
Glioblastoma Multiforme, Glioblastoma, Adult
A Phase II/III Study of High-dose, Intermittent Sunitinib in Patients With Recurrent Glioblastoma Multiforme
In this study the investigators will evaluate the effect of high-dose, intermittent sunitinib versus treatment with lomustine in patients with recurrent glioblastoma multiforme.
- Conditions
- Glioblastoma Multiforme, Glioblastoma, Adult, Glioblastoma, Recurrent Brain Tumor
- Trial name
- STELLAR (NCT03025893)
- Testing
- Sunitinib, Lomustine
- Where
- 3 sites in Netherlands
- Volunteers
- 100 people
- Sponsor
- Amsterdam UMC, location VUmc
Recurrent Glioblastoma Multiforme (GBM)
Efficacy and Safety of Imatinib Mesylate Plus Hydroxyurea (HU) in Patients With Recurrent Glioblastoma Multiforme (GBM)
This was an investigational study to assess the objective overall response (OOR) rate (complete response [CR] + partial response [PR]) of imatinib mesylate and hydroxyurea (hydroxycarbamide) combination therapy in patients with…
- Trial name
- NCT00290771
- Testing
- Imatinib tablets, Hydroxyurea capsules
- Where
- United States
- Volunteers
- 231 people
- Sponsor
- Novartis